Arex Capital Loads Caly: A Bold Bet on CALY Stock
A fresh SEC filing shows AREX Capital Management opening a new stake in CALY with 453,000 shares worth about $5.29 mi...
Glide paths in target date funds describe how asset allocations shift automatically as retirement nears, balancing growth and risk over time. This intro explains the idea and why it matters for planning.
25,488 articlesA fresh SEC filing shows AREX Capital Management opening a new stake in CALY with 453,000 shares worth about $5.29 mi...
The latest CPI data shows inflation moving in a way it hasn’t in years. This could shift Fed policy and rock the stoc...
A promised Europe adventure collapsed, leaving families with unrefunded costs. This guide explains restitution, red f...
SVB Capital, the bank's roughly $10 billion venture arm, is being shopped as regulators unwind SVB assets. Buyers are...
Three key ETFs are steering the reshoring trend in critical minerals as China tightens export controls. REMX, LIT, an...
A sudden health update can ripple into finances. This guide turns that news into practical steps you can take today t...
Six AI-driven forecasts clash with Standard Chartered’s trimmed XRP target, spotlighting how ETF dynamics and policy ...
A trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
An 8% jump can feel exciting, but a smart investor asks: what’s next? This guide breaks down how to assess a sudden m...
Choosing a small-cap ETF can feel overwhelming. This guide breaks down SPSM vs. VB, explains how each index works, an...
Choosing between a climate-focused global ETF and an emerging markets fund isn’t just about returns. This guide break...
A big stock move and a buyout rumor are reshaping how traders view NCR Atleos. A large block sale drew attention, jus...